

510(k) SUMMARY

1000617

Submitted by: Masimo Corporation
40 Parker
Irvine, CA 92618
949-297-7000
FAX 949-297-7592 **MAY 28 2010**

Company Contact: Marguerite Thomlinson, Manager of Regulatory Affairs

Date Summary Prepared: March 2, 2010

Trade Name: Masimo Resposable Oximetry Sensors

Common Name: Oximeter Sensor

Regulation Number: 21 CFR 870.2700

Regulation Name: Oximeter

Regulation Class: Class II

Product Code: DQA, DSA

Substantially Equivalent Devices: LNCS Oximetry Sensors, 510k) No. K051212
Masimo Rainbow Resposable Sensors, 510(k) No. K090165

Device Description

The Masimo Resposable Oximetry Sensors (S2 Sensors) are fully compatible for use with instruments which include or compatible with the following technologies:

- Masimo SET technology
- Masimo Rainbow SET technology
- Nellcor technology
- Philips FAST-SpO₂ technology

The S2 Sensors and the predicates (K051212), the LNCS Oximetry Sensors (LNCS Sensors), have the same indications for use/ intended use. The S2 Sensors also have the same sensor design as the predicates (K090165), the Masimo Rainbow Resposable Sensor (R2 Sensors). The reason for this filing is to modify the LNCS Sensor design.

Predicate Device

The predicate devices used in this filing are:

- The LNCS Oximetry Sensors (LNCS Sensors), 510(k) No. K051212
- The Masimo Rainbow Resposable Sensors (R2 Sensors), 510(k) No. K090165.

510(k) SUMMARY

Intended Use/ Indications for Use

The Masimo Resposable Oximetry Sensors are indicated for the continuous noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO_2) and pulse rate (measured by an SpO_2 sensor) for use with adult and pediatric patients, during both no motion and motion conditions, and for patients who are well or poorly perfused in hospitals, hospital-type facilities, mobile, and home environments.

Technology Comparison

The S2 Sensors are substantially equivalent to the predicate sensors in the design, principles of operation, and performance. The S2 Sensors and the predicates operate on identical principles of non-invasive optical assessment of tissue oxygenation using emitters and detectors.

Specifications

The specifications for the S2 Sensors are as following:

Masimo SET® Technology and Masimo Rainbow SET® Technology (Adults > 20kg; Pediatrics 10-50kg)		
Measurement	Accuracy Range	Accuracy
Arterial Oxygen Saturation (SpO_2), No Motion	70-100%	$\pm 2\%$
Arterial Oxygen Saturation (SpO_2), Motion	70-100%	$\pm 3\%$
Arterial Oxygen Saturation (SpO_2), Low Perfusion	70-100%	$\pm 2\%$
Pulse Rate, No Motion	25-240 bpm	± 3 bpm
Pulse Rate, Motion	25-240 bpm	± 5 bpm
Pulse Rate, Low Perfusion	25-240 bpm	± 3 bpm

Nellcor® Technology and Philips® FAS™ SpO₂ Technology (Adults > 20kg; Pediatrics 10-50kg)		
Measurement	Accuracy Range	Accuracy
Arterial Oxygen Saturation (SpO_2), No Motion	70-100%	$\pm 2\%$
Pulse Rate, No Motion	25-240 bpm	± 3 bpm

Test Summary

The S2 Sensors comply with the voluntary standards as detailed in this submission. The following quality assurance measures were applied to the development of the S2 Sensors:

- Risk Analysis
- Design Reviews
- Biocompatibility Testing
- Performance Testing
- Safety Testing

Conclusions

The information in this 510(k) submission demonstrates that the S2 Sensors are substantially equivalent to the predicate devices, with respect to safety, effectiveness, and performance.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room - WO66-G609
Silver Spring, MD 20993-0002

Ms. Marguerite Thomlinson
Manager of Regulatory Affairs
Masimo Corporation
40 Parker
Irvine, California 92618

MAY 28 2010

Re: K100617

Trade/Device Name: Masimo Resposable Oximetry Sensors
Regulation Number: 21 CFR 870.2700
Regulation Name: Oximeter
Regulatory Class: II
Product Code: DQA
Dated: April 26, 2010
Received: April 29, 2010

Dear Ms. Thomlinson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2- Ms. Marguerite Thomlinson

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to

<http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

<http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
<http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "A. D. Watson" followed by "for".

Anthony D. Watson, B.S., M.S., M.B.A.
Director
Division of Anesthesiology, General Hospital,
Infection Control and Dental Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Indications for Use

510(k) Number (if known): _____

Device Name: Masimo Resposable Oximetry Sensors

Indications For Use:

The Masimo Resposable Oximetry Sensors are indicated for the continuous noninvasive monitoring of functional oxygen saturation of arterial hemoglobin (SpO₂) and pulse rate (measured by an SpO₂ sensor) for use with adult and pediatric patients during both no motion and motion conditions, and for patients who are well or poorly perfused in hospitals, hospital-type facilities, mobile, and home environments.

Prescription Use X
(Per 21 CFR 801.109 Subpart D)

AND/OR

Over-The-Counter Use _____
(Per 21 CFR 801.109 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)

Division of Anesthesiology, General Hospital
Infection Control, Dental Devices